BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Au KP, Chok KSH. Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? World J Gastrointest Surg 2020; 12(4): 149-158 [PMID: 32426094 DOI: 10.4240/wjgs.v12.i4.149]
URL: https://www.wjgnet.com/1007-9327/full/v12/i4/149.htm
Number Citing Articles
1
Kin Pan Au, James Yan Yue Fung, Wing Chiu Dai, Albert Chi Yan Chan, Chung Mau Lo, Kenneth Siu Ho Chok. Verifying the Benefits of Radical Treatment in Posttransplant Hepatocellular Carcinoma Oligo‐recurrence: A Propensity Score AnalysisLiver Transplantation 2022; 28(1): 51 doi: 10.1002/lt.26251
2
Ina Y. Aneva , Solomon Habtemariam, Maciej Banach, Parames C. Sil , Kasturi Sarkar, Adeleh Sahebnasagh , Mohammad Amjad Kamal, Maryam Khayatkashani, Hamid Reza Khayat Kashani. Can We Use mTOR Inhibitors for COVID-19 Therapy?Combinatorial Chemistry & High Throughput Screening 2022; 25(11): 1805 doi: 10.2174/1386207325666211130140923
3
Luckshi Rajendran, Tommy Ivanics, Marco PAW Claasen, Hala Muaddi, Gonzalo Sapisochin. The management of post-transplantation recurrence of hepatocellular carcinomaClinical and Molecular Hepatology 2022; 28(1): 1 doi: 10.3350/cmh.2021.0217
4
Kin-Pan Au, James Yan-Yue Fung, Wing-Chiu Dai, Albert Chi-Yan Chan, Chung-Mau Lo, Kenneth Siu-Ho Chok. Impact of Tumour Biology on Outcomes of Radical Therapy for Hepatocellular Carcinoma Oligo-Recurrence after Liver TransplantationJournal of Clinical Medicine 2022; 11(15): 4389 doi: 10.3390/jcm11154389
5
Faiza Ahmed, Faiza Zakaria, Godsgift Enebong Nya, Mohamad Mouchli. Sirolimus <i>vs</i> tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?World Journal of Gastrointestinal Surgery 2022; 14(8): 862-866 doi: 10.4240/wjgs.v14.i8.862
6
Sezai Yilmaz, Volkan Ince. The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver TransplantationJournal of Gastrointestinal Cancer 2021; 52(4): 1350 doi: 10.1007/s12029-021-00716-9
7
Kin Pan Au, Kenneth Siu Ho Chok. Immunotherapy after liver transplantation: Where are we now?World Journal of Gastrointestinal Surgery 2021; 13(10): 1266 doi: 10.4240/wjgs.v13.i10.1266
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
8
Ishfaq Hassan Mir, Shreyoshi Guha, Jajnasenee Behera, Chinnasamy Thirunavukkarasu. Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapyCell Biology International 2021; 45(11): 2161 doi: 10.1002/cbin.11670
9
Kin Pan Au, Kenneth Siu Ho Chok. Immunotherapy after liver transplantation: Where are we now?World Journal of Gastrointestinal Surgery 2021; 13(10): 1267-1278 doi: 10.4240/wjgs.v13.i10.1267
10
Xiangyu Yan, Songhan Huang, Yang Yang, Ziwen Lu, Feiyu Li, Liyong Jiang, Yong Jiang, Jun Liu. Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta‐AnalysisLiver Transplantation 2022; 28(6): 1063 doi: 10.1002/lt.26387
11
Kin-Pan Au, Wing-Chiu Dai, Albert Chi-Yan Chan, Tan-To Cheung, Chung-Mau Lo, Kenneth Siu-Ho Chok. Performance of Dual-tracer PET-CT for Staging Post–Liver Transplant Hepatocellular Carcinoma RecurrenceTransplantation Direct 2021; 7(10): e769 doi: 10.1097/TXD.0000000000001213